An organic electroluminescence device inducting a cathode, an anode, and an emitting layer disposed between the cathode and the anode, wherein the emitting layer includes a compound represented by the following formula (1) and one or more compounds selected from the group consisting of compounds represented by each of formulas (11), (21), (31), (41), (51), (61), (71) and (81). In the formula (1), at least one of R.sub.1 to R.sub.8 is a deuterium atom,

##STR00001##

The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.

The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.

Disclosed herein is an organic light-emitting diode capable of operating at a low voltage with high efficiency. It comprises: a first electrode; a second electrode facing the first electrode; and a light-emitting layer interposed between the first electrode and the second electrode, wherein the light-emitting layer comprises at least one of the amine compounds represented by the following Chemical Formula A or B, and the compound represented by the following Chemical Formula C. Chemical Formulas A, B and C are as described in the Specification.

Disclosed herein is an organic light-emitting diode capable of operating at a low voltage with high efficiency. It comprises: a first electrode; a second electrode facing the first electrode; and a light-emitting layer interposed between the first electrode and the second electrode, wherein the light-emitting layer comprises at least one of the amine compounds represented by the following Chemical Formula A or B, and the compound represented by the following Chemical Formula C. Chemical Formulas A, B and C are as described in the Specification.

Provided herein are compounds of Formulae (RL), (I), (II), (HI), (IV), and (V), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, prodrugs, and isotopically labeled derivatives thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment of metabolic disorders (e.g., diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, obesity). The compound are useful as substrate selective inhibitors of insulin-degrading enzyme (IDE).

##STR00001##

Provided herein are compounds of Formulae (RL), (I), (II), (HI), (IV), and (V), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, prodrugs, and isotopically labeled derivatives thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment of metabolic disorders (e.g., diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, obesity). The compound are useful as substrate selective inhibitors of insulin-degrading enzyme (IDE).

##STR00001##

An organic electroluminescence device includes a first electrode, a hole transport region disposed on the first electrode, an emission layer disposed on the hole transport region, an electron transport region disposed on the emission layer, and a second electrode disposed on the electron transport region, wherein the hole transport region includes a polycyclic compound represented by Formula 1, and the device shows high emission efficiency:

##STR00001##

The invention relates to compounds constituting C20-N-acyl derivatives of salinomycin with the general formula (2):

##STR00001##

and their salts, where X denotes R, O—R or NH—R, and R is as defined in the claims and in the description. The invention also relates to a composition comprising the compound defined above and at least one pharmaceutically acceptable excipient. The invention also relates to a method for obtaining salinomycin derivatives with the general formula (2), as well as an intermediate product for obtaining these compounds. The invention also relates to compounds constituting C20-N-acyl derivatives of salinomycin with the general formula (2) for use as a medicament, particularly as anti-cancer agents.

The invention relates to compounds constituting C20-N-acyl derivatives of salinomycin with the general formula (2):

##STR00001##

and their salts, where X denotes R, O—R or NH—R, and R is as defined in the claims and in the description. The invention also relates to a composition comprising the compound defined above and at least one pharmaceutically acceptable excipient. The invention also relates to a method for obtaining salinomycin derivatives with the general formula (2), as well as an intermediate product for obtaining these compounds. The invention also relates to compounds constituting C20-N-acyl derivatives of salinomycin with the general formula (2) for use as a medicament, particularly as anti-cancer agents.